GERN - Geron started at overweight at Barclays following imetelstat approval June, 10 2024 10:25 AM Geron Corporation 2024-06-10 10:25:57 ET More on Geron Geron: Innovative Rytelo Enters A Challenging MDS Market Geron Corporation: A High-Risk Deal With A Good Chance Of Success Geron jumps as FDA approves lead asset for blood cancer Geron Corporation (GERN) Q1 2024 Earnings Call Transcript For further details see: Geron started at overweight at Barclays following imetelstat approval